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Over the past decade, RNA interference (RNAi) plays an important role in biology, especially for 
silencing gene expression. RNA interference (RNAi) is a natural process through which expression of a 
targeted gene can be knocked down with high specificity and selectivity. Methods of mediating the RNAi 
effect involve small interfering RNA (siRNA) and short hairpin RNA (shRNA). In various applications, 
RNAi has been used to create model systems, to identify novel molecular targets, to study gene 
function in a genome-wide fashion, and to create new avenues for clinical therapeutics. This article 
reviews the current knowledge on the mechanism and applications of shRNA in mammalian and human 
cells. 
 





In the last few years, RNA interference (RNAi) has become 
an important topic in biological research, and is predicted 
one of the great achievements in the next decades. RNAi 
is a method based on post-transcriptional gene silencing 
(PTGS) mechanism which is initiated by double strands 
RNA (>30nt), small interfering RNA or short hairpin RNA 
(shRNA) (<30nt). PTGS was first described in plants, 
when attempts to increase chalcone synthase expression 
in petunias result in the effective suppression of both the 
endogenous gene as well as introduced gene, which was 
called “cosuppression” (Napoli et al., 1990). After that, 
Guo used antisense strand RNA which is complementary 
to mRNA to suppress the expression of specific gene in 
Caenorhabditis elegans, meanwhile, injecting sense strand 
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sequence silencing (Guo and Kemphues, 1995). It was 
finally interpreted in 1998 by Fire in the nematode worm 
C. elegans that dsRNA was substantially more effective 
than ssRNA in gene silencing and it was named “RNA 
interference” (Fire et al., 1998). Later, the RNAi phenol-
menon was found in a wide variety of organisms, such as 
Drosophila (Hammond et al., 2000; Misquitta and 
Paterson, 1999), planaria (Sanchez and Newmark, 1998), 
trypanosomes (Ngo et al., 1998), hydra (Lohmann et al., 
1999), zebrafish (Wargelius et al., 1999) and also 
mammals (Elbashir et al., 2001). 
RNAi can serve as a powerful tool for inhibiting gene 
expression with dsRNA; however, there are some 
obstacles in most mammalian cells which are complicated 
by nonspecific gene. This happens because introduction 
of long dsRNA (>30nt) activates a potent antiviral res-
ponse (Manche et al., 1992; Minks et al., 1979; Williams, 
1997). In addition, Manche showed that activated PKR 
results in a generalized repression of translation (Manche 
et al., 1992), and RNase L also leads nonspecific gene 
silencing (Minks et al., 1979). The enzyme dsRNA-
dependent protein kinase(PKR) is activated when binding 
to dsRNA, while sequence-independent induces the 
repression of protein synthesis (Williams, 1997). There-
fore, the application of siRNAs (<30nt) achieved in 





RNAi mechanism (Elbashir et al., 2001). This siRNAs 
avoid the antiviral response in mammalian cells. 
Originally, the chemically synthesized siRNAs were 
used in experiments effectively, though costly. In order to 
reduce the cost, many researchers designed plasmid 
expression vectors to generate sustained production of 
siRNA (Vermeulen et al., 2005; Hannon and Rossi, 2004; 
Bartel, 2004; Liu et al., 2003). The majority of siRNAs 
expression vector rely on one promoter of RNA poly-
merase III to control the expression of short hairpin RNA 
(shRNA) in mammalian cells. This promoter contains the 
U6 snRNA promoter of man and mice, and H1 RNA 
promoter of RnaseP (Zamore et al., 2000; Zhang et al., 
2002; Myers et al., 2003). These vectors contain a DNA 
sequence that encodes the shRNA cloned between the 
promoter and a transcription terminated at position 2 of 
the termination site and then folds into a stem-loop 
structure with 3'UU-overhangs. In most cases, pol III 
promoter was used to direct the expression of shRNA 
more effectively. This pol III promoter contains all neces-
sary components of RNA upstream and terminates in a 
short of thymidine gather. Once shRNA is expressed, it is 
shifted in the cytoplasm and processed to siRNA by Dicer 
(Vermeulen et al., 2005). 
 
 
DICER SPECIFICITY AND EFFICIENCY 
 
At a key stage of the RNAi pathway, the ribonuclease 
(RNase) III-like enzyme Dicer, processes long double-
stranded RNA dsRNA) or pre-microRNA hairpin precur-
sors into small interfering RNAs (siRNAs) or microRNA 
(miRNAs) (Hannon and Rossi, 2004; Bartel, 2004). 
These short RNAs are then loaded into the RNA induced 
silencing complex (RISC) through the action of R2D2 and 
Dicer (Liu et al., 2003). The 21–23-nt products of Dicer 
digestion contain characteristic 2-nt 3_ overhangs and 
act as the functional intermediates of RNAi directing 
mRNA cleavage and translational attenuation. Aware-
ness of these new features of Dicer cleavage specificity 
as it is related to siRNA functionality provides a more 
detailed understanding of the RNAi mechanism and can 
shape the development of hairpins with enhanced 
functionality. While details of Dicer’s functional domains 
are being elucidated, less is known about the contri-
butions that the dsRNA substrate makes to position and 
efficiency of Dicer cleavage. Dicer generates 20 base-
pair (bp) siRNAs by entering the duplex from the termini 
(Zamore et al., 2000; Zhang et al., 2002) and cleaves 
both short (30 nt) and long (130 nt) dsRNA molecules 
with equal efficiency (Elbashir et al., 2001; Myers et al., 
2003). In contrast, smaller duplexes (21 nt siRNAs) do 
not appear to bind Dicer in vitro (Provost et al., 2002). 
While substrates with 3_ overhangs are more efficiently 
processed than blunt ended molecules, the state of 5_ 
phosphorylation of the duplex does not play a role in 
efficiency (Zhang et al., 2002; Zhang et al., 2004). 




Cleavage studies of substrates with varying overhang 
lengths revealed additional contributions of the substrate 
to Dicer specificity. It has been observed that as the 
length of the overhang increases from 1 to 3 nt, the 
position of the preferred Dicer cleavage site shifts 
(Vermeulen et al., 2005). In contrast, as overhang length 
increased beyond 3 nt, the position of cleavage on the 
complementary strand remained constant (that is sub-
strates with 3-nt, 4-nt, and 5-nt overhangs show roughly 
equivalent cleavage site preferences). These obser-
vations lend to the hypothesis that when a molecule is 
blunt or when an overhang of 1–3 nt is present, Dicer 
recognizes the 3’-end of the molecule and cuts at a fixed 
distance from the end. When that overhang length is 
exceeded, the rules governing PAZ domain recognition 
are altered and other interactions (presumably mediated 
through the dsRBD) play a more dominant role in 
determining how Dicer orients itself (Vermeulen et al., 
2005). The polymerase III promoter/terminator is often 
used in vector-based shRNA expression design 
(Brummelkamp et al., 2002) and results in an shRNA 
containing a variable 3’-end of approximately 1–4 nt 
(Bogenhagen and Brown, 1981; Miyagishi and Taira, 
2002). As shown in these studies, 3’-overhang lengths of 
1–3 nt generate overlapping yet distinctly different 
preferred products; the use of current expression 
systems may lead to a range of desirable and undesir-
able cleavage products and impaired silencing.  
 
 
MECHANISM OF shRNA INTERFERENCE 
 
Until now several studies have shed light on the 
underlying mechanisms of how RNAi works. The current 
model of the RNAi mechanism includes both initiator and 
effector steps (Provost et al., 2002; Zhang et al., 2004; 
Brummelkamp et al., 2002; Bogenhagen and Brown, 
1981). First, the dsRNAs get processed into 20-25 
nucleotide (nt) small interfering RNAs (siRNAs) by an 
RNase III-like enzyme called Dicer (initiation step). Then, 
the siRNAs assemble into endoribonuclease-containing 
complexes known as RNA-induced silencing complexes 
(RISCs), unwinding in the process. The siRNA strands 
subsequently guide the RISCs to complementary RNA 
molecules, where they cleave and destroy the cognate 
RNA (effecter step). Cleavage of cognate RNA takes 
place near the middle of the region bound by the siRNA 
strand. RISC is activated by the ATP-dependent unwinding 
of the siRNA duplex. Activated RISC splices the target 
mRNA at the site of homologous sequence (Elbashir et 
al., 2001; Manche et al., 1992). Then the antisense 
strand of the siRNA guides cleavage of targeted mRNAs. 
Activate RISC through base pairing mRNA homologous 
position to the transcription, and cleave the mRNA at 12 
nt from 3' position of siRNA. Finally, the degradation of 
mRNA results in the target gene silencing (Zhang et al., 
2004;   Brummelkamp   et   al.,   2002;  Bogenhagen  and 




Brown, 1981; Miyagishi and Taira, 2002). 
 
 
ESTABLISHING RNA INTERFERENCE IN 
MAMMALIAN SYSTEMS 
 
RNAi induced by long dsRNA has been used to study 
gene function in plants, worms and Drosophila. In 
particular, studies in C. elegans and Drosophila have 
shown that using dsRNA to induce RNAi is effective in 
generating models for the analysis of genes involved in 
cell division or development (Gonczy et al., 1999; 
Jantsch-Plunger and Glotzer, 1999; Kennerdell and 
Carthew, 1998). However, when dsRNAs more than 30 
bp in length were used to study mammalian gene 
function, it was noted that there was an inhibition of 
protein translation within the cell due to the activation of 
the interferon (IFN) system (one of the body’s defense 
against viral infection) (Provost et al., 2002). Over 100 
cellular genes can be activated by IFNs and some 
encode enzymes that are dsRNA-binding proteins. This 
includes protein kinase R (PKR) which phosphorylates 
and inactivates eukaryotic initiation factor 2 and hence 
inhibits mRNA translation (Manche et al., 1992). 
Therefore, to apply RNAi technology to studies using 
mammalian systems (without inducing an IFN response), 
the silencing pathway had to be induced without the use 
of long dsRNA. Since synthetic 21–22 bp-long siRNAs 
could bypass the initial Dicer step while retaining the 
ability to mediate gene silencing in Drosophila, they were 
used in studies using mammalian cells.  
A number of groups have designed plasmid expression 
vectors to generate sustained production of siRNAs by 
transient or stable transfection. Some of these vectors 
have been engineered to express small hairpin RNAs, 
which are processed in vivo into siRNA-like molecules 
capable of carrying out gene-specific silencing 
(Brummelkamp et al., 2002; Paddison et al., 2002; Paul 
et al., 2002; Yu et al., 2002). After construction is 
complete, these vectors contain a DNA sequence that 
encodes the shRNA cloned between a Pol III promoter 
and a transcription termination site comprising 4–5 
thymidine residues. The transcript is terminated at 
position 2 of the termination site and then folds into a 
stem-loop structure with 3' UU-overhangs. The ends of 
the shRNAs are processed in vivo, converting the shRNA 
into ~21 nt siRNA-like molecules, which in turn initiate 
RNAi (Brummelkamp et al., 2002). These vectors repre-
sent a definite improvement in initiating RNAi in cells; 




KNOCKOUT RNAi SYSTEM 
 
With further understanding of RNAi mechanism, shRNAs 





purpose of silencing specific homologous mRNA expres-
sion in mammalian cells. Since RNAi may not totally 
abolish expression of the gene, this technique is some-
times referred as a "knockdown", to distinguish it from 
"knockout" procedures in which expression of a gene is 
entirely eliminated (Voorhoeve and Agami, 2003). The 
knockout RNAi systems allow you to quickly express 
functional hairpin siRNA molecules in mammalian cells 
for the purpose of silencing target genes. These systems 
include RNAi-Ready pSIREN Vectors that use the cell's 
own RNA Polymerase III (Pol III) to transcribe a 
specifically designed small hairpin RNA (shRNA) using 
the human U6 promoter. The human U6 promoter provi-
des a high level of expression in many cell types (Kunkel 
and Pederson, 1989), resulting in target gene suppression. 
shRNA oligonucleotide design describes the process of 
identifying target sequences within a gene of interest and 
designing the corresponding oligonucleotides to generate 
the shRNA. This could be achieved by (i) Selecting a 
region of 19 nt; do not choose the region near the start 
codon (within 75 bases), nor untranslated regions 
(Elbashir et al., 2001). (ii) Avoid selecting target sense or 
antisense sequences that contain a consecutive run of 3 
or more thymidine residues; a poly(T) tract within the 
sequence can potentially cause premature termination of 
the shRNA transcript. (iii) Ensuring the content of GC of 
the 19-bases oligonucleotide between 40-60%, and a GC 
content of approximately 45% is ideal. (iv) Examining the 
19-bases oligonucleotide for secondary structure and 
long base runs, both of which can interfere with the 
process of annealing. The 19-base oligonucleotide is 
specific gene of the interest, without homology to other 
genes. (v) With 7-9 nt hairpin loop sequence between 
sense and antisense strand (Vermeulen et al., 2005; 
Hannon and Rossi, 2004; Bartel, 2004; Gonczy et al., 
1999; Jantsch-Plunger and Glotzer, 1999), the most 
effective sequence is 5’-TTCAAGAGA-3’ after compa-
rison of different length and sequence of stem-loop. The 
end of two complementary oligonucleotides must have 
the restriction site. 5-6 T must be placed at the end of 
shRNA to ensure the termination of RNA polymerase III 
transcription (Figure 1). 
Figure 1 shows the generated shRNA using an oligo-
nucleotide DNA sequence. The hairpin loop sequence is 
located between the sense sequence and antisense 
sequence on the complementary DNA strand. ShRNA 
includes two short reverse-sequences, having a stem-
loop sequence at the middle, with composition of the 
hairpin structure, controlled by poly promoter. Then it 




APPLICATION OF shRNA INTERFERENCE  
 
The studies on shRNA have been performed on an 
increasingly routine basis.  The  innovation  of  RNAi  has 
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revolutionized the study of gene function in model 
organisms and promises to permit large-scale loss-of-
function studies in mammals. Because of the potential 
effectiveness of RNAi, it has become the methodology 
and technology for silencing specific gene expression in 
mammalian cells. The RNAi machinery can recognize 
invading double-stranded viral RNA (or the double-
stranded replicative form of the viral RNA) and suppress 
the infection by degradation of the RNA. The RNAi 
system thus shares important features with the vertebrate 
immune system: it recognizes the invading parasite 
(dsRNA) raises an initial response and subsequently 
amplifies the response to eliminate the foreign element. 
The application of RNAi technology from genomics research 
has been gradually expanded to the medical field and as 
a means of gene therapy. Utilize RNAi not only provide 
an economic fortunes but also open up a new thinking 
with the gene function measurement and gene therapy. 
The application of RNAi using shRNA in vivo is now used 
in mice commonly. Despite the problems of delivery, RNA 
interference has been used effectively in the mouse to 
block expression of a hepatitis C virus protein in the liver 
(McCaffrey et al., 2002). In addition, the same group has 
used specific RNA interference to block hepatitis B virus 
infection in mice (McCaffrey et al., 2003). They achieved 
delivery by injecting large amounts of synthetic double 
stranded RNA or DNA encoding a short hairpin RNA into 
the portal vein. This is a transient silencing of sequences, 
and was done by injecting shRNA into high-pressure tail 
vein (Grimm et al., 2006). Grimm et al. (2006) have 
shown that high expression of shRNAs can result in high 
lethality of mice. It is demonstrated that the endogenous 
miRNAs can be disrupted by high shRNA expression not 
only in cell culture, but also in vivo (Grimm et al., 2006). 
The expression of shRNAs can induce an interferon 
response (Bridge et al., 2003). When human embryonic 
kidney 293 (HEK293) or keratinocyte (HaCaT) cell lines 
or human primary dendritic cells or macrophages were 
transfected with siRNA or shRNAs, suppression of non-
targeted mRNA expression was detected (Kariko et al., 
2004). 
In recent years, therapies based on RNAi are being 
used to attenuate viral infection in cell culture or animal 
experiments, which include foot-and-mouth disease virus, 
influenza virus, hepatitis B (HBV) and C virus (HCV), 
respiratory syncytial virus (RSV) and human immuno-
deficiency virus (HIV). RNAi is well suited as an antiviral 
therapy for numerous reasons. The majority of anti-HIV 
small molecule drugs used in highly active antiretroviral 
therapies (HAART) focus on one of two viral enzymes, 
reverse transcriptase and protease (Clavel and Hance, 
2004). In addition, the RNAi-inducing nucleic acids must 
be delivered within a therapeutic window of dosage, as 
dose-dependence has been observed both in vitro and in 
vivo. Lentiviral vector delivery of shRNA-expressing cons-
truct progressively knocked down target gene expression 
in single cells with increasing viral dosage (Abbas-Terki et 
al., 2002).   
Strategies based on RNAi have been introduced to 
treat different kinds of liver diseases. Especially hepatitis, 
such as HBV and HCV, both of them increased the 
chronic   liver  disease  and  hepatocellular  carcinoma  in 




humans. Recent researchers focused on therapies using 
RNAi to treat this disease. Transfecting an HBV plasmid 
expressing shRNAs in cell and mice can induce RNAi 
reponse, that HBV replication can be inhibited (McCaffrey 
et al., 2003). A similar approach was taken to target the 
Fas protein, an important inducer of programmed cell 
death, resulting in protection of mice from fulminant 
hepatitis caused by injection with agonistic Fas-specific 
antibodies (Song et al., 2003). The advantages of shRNA 
expression vector can be a long-term study. Many 
researchers have shown that the vector carried with 
antibiotics marked in the cells can sustain inhibition gene 
expression for weeks or longer. shRNA can be engin-
eered to suppress the expression of desired genes in cell 
stability (Paddison et al., 2002). 
Initial research on RNAi using shRNA in vivo was 
plasmid DNA (Lewis et al., 2002). With the advancement 
of modem science and technology, researchers have 
devoted to the use of viral vectors. Choosing the viral 
system depends on the type of cell and the need of short-
term or long-term express shRNA. Citing two different 
response-time requirements: Short-term expression is 
used for adenovirus (AV) and herpes simplex viral vector 
system mainly while long-term expression is used for 
adeno-associated viral (AAV) vector systems frequently. 
A large number of RNAi-based screening systems have 
been described in recent years (Song et al., 2003; 
Paddison et al., 2002; Lewis et al., 2002; Mullenders et 
al., 2009).This system uses external shRNAs into viral 
vector plasmid, which could be activated by RNA 
polymerase III promoters . 
The shRNAs produced a wide range of clinical effects, 
ranging from benign to malignant tumours, the severity 
and type of which correlated with the extent to which the 
shRNA had silenced p53. An shRNA barcode technique 
was used to identify novel genes which regulate p53 
function from a complex mixture (Mullenders et al., 2009). 
In addition, novel tumor suppressors were also identified 
using shRNAs that transformed human primary cells 
(Kolfschoten et al., 2005). Recently, researchers deve-
loped a vector that mediates suppression of gene 
expression through RNA interference. Here, they used a 
retroviral version of this vector to specifically and stably 
inhibit expression of only the oncogenic K-RASV12 allele 
in human tumor cells (Brummelkamp et al., 2002). It is 
found that shRNA expressed from viral vectors can be 
used to mediate RNA interference to induce persistent 
loss-of–function phenotypes. Then, also a test was con-
ducted on the tumorigenic capacity of CAPAN-1 cell in 
vivo, by injecting subcutaneously in mice. These proved 
the ability of RNAi-mediated silencing to suppress tumor 
formation in vivo (Brummelkamp et al., 2002). 
Libraries of RNA interference molecules have been 
constructed that allow the analysis of gene function on a 
genome-wide scale. One group screened pools consist of 
retroviruses and identified components of the p53 
pathway using large libraries of shRNA-expressing 





screened by transfecting cells with shRNA-expressing 
retroviral plasmids and identified genes involved in 
proteasome function (Silva et al., 2005). Recently, the 
same two libraries were used to identify two novel tumor-
suppressor genes (Westbrook et al., 2005). While these 
reports establish the precedent that shRNA libraries can 
be employed to perform loss-of-function screens in 
mammalian cells, it is clear that further exploration of the 
performance characteristics and limitations of such 
approaches is necessary before such large-scale applica-
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RNA interference, the biological mechanism by which 
double-stranded RNA (dsRNA) induces gene silencing by 
targeting complementary mRNA for degradation, is revo-
lutionizing the way researchers study gene function. For 
the first time, scientists can quickly and easily reduce the 
expression of a particular gene in nearly all metazoan 
systems, often by 90% or greater, to analyze the effect 
that gene has on cellular function. In recent years, 
scientists have co-opted this biological process to reduce 
the expression of target mRNAs by using exogenously 
applied siRNAs and shRNAs. Aside from the widespread 
basic biological applications of RNAi, the ability to reduce 
gene expression marks a major advance toward the 
development of disease therapies, particularly for domi-
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